NASDAQ : CBIO
Crescent Biopharma, Inc. — Financial statements
Healthcare · Biotechnology · United States
Last price 13.39 USD (Oct 30, 2026, 2:56 PM EDT) · Market cap 573.11M
Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports
Financial statements
Crescent Biopharma, Inc. (CBIO) reported revenue of 11.88M USD (TTM). Five years of income statement, balance sheet, cash flow and ratios below.
Income statement
Fiscal year January - December; amounts in USD.
| TTM | FY2025 | FY2024 | |
|---|---|---|---|
| Revenue | 11.88M | 10.84M | |
| Gross Profit | 11.88M | 10.84M | |
| Selling, General & Admin | 29.45M | 25.39M | 12.63M |
| Research & Development | 152.67M | 138.09M | 56.14M |
| Operating Expenses | 182.12M | 163.48M | 68.76M |
| Operating Income | -170.24M | -152.63M | -68.76M |
| Interest Expense | -2.19M | -3.41M | |
| Interest & Investment Income | 5.35M | 2.88M | 704.00K |
| Pretax Income | -163.12M | -151.94M | -71.47M |
| Income Tax Expense | 2.00M | 2.00M | |
| Net Income | -165.12M | -153.94M | -71.47M |
| Net Income to Common | -165.12M | -153.94M | -71.47M |
| Shares Outstanding (Basic) | 27.38M | 12.01M | 767.58K |
| Shares Outstanding (Diluted) | 27.38M | 12.01M | 767.58K |
| EPS (Basic) | -6.03 | -12.81 | -93.11 |
| EPS (Diluted) | -6.03 | -12.81 | -93.11 |
| Free Cash Flow | -73.62M | -72.45M | -25.08M |
| Free Cash Flow Per Share | -2.69 | -6.03 | -32.67 |
| Gross Margin | 100.00% | 100.00% | |
| Operating Margin | -1,432.63% | -1,407.53% | |
| Profit Margin | -1,389.58% | -1,419.61% | |
| Free Cash Flow Margin | -619.52% | -668.12% | |
| EBITDA | -170.03M | -152.55M | |
| D&A For EBITDA | 212.00K | 84.00K | |
| EBIT | -170.24M | -152.63M | -68.76M |
Balance sheet
Fiscal year January - December; amounts in USD.
| TTM | FY2025 | FY2024 | |
|---|---|---|---|
| Cash & Equivalents | 171.59M | 213.19M | 34.77M |
| Cash & Short-Term Investments | 171.59M | 213.19M | 34.77M |
| Receivables | 18.00M | ||
| Prepaid Expenses | 7.41M | 5.46M | 38.00K |
| Total Current Assets | 179.01M | 236.66M | 34.80M |
| Property, Plant & Equipment | 2.15M | 2.31M | |
| Other Long-Term Assets | 1.60M | 1.32M | 813.00K |
| Total Assets | 182.76M | 240.29M | 35.62M |
| Accounts Payable | 2.54M | 10.00M | 107.00K |
| Accrued Expenses | 7.41M | 8.48M | 9.45M |
| Current Portion of Leases | 471.00K | 435.00K | |
| Current Unearned Revenue | 3.12M | 4.16M | |
| Other Current Liabilities | 5.00M | 13.00M | 61.00K |
| Total Current Liabilities | 18.54M | 36.07M | 9.61M |
| Long-Term Debt | 37.48M | ||
| Long-Term Leases | 966.00K | 1.21M | |
| Total Liabilities | 19.50M | 37.28M | 47.10M |
| Common Stock | 28.00K | 28.00K | 1.00K |
| Additional Paid-In Capital | 379.16M | 370.79M | 2.39M |
| Retained Earnings | -219.93M | -171.81M | -17.87M |
| Total Common Equity | 159.25M | 199.01M | -15.48M |
| Shareholders' Equity | 163.25M | 203.01M | -11.48M |
| Total Liabilities & Equity | 182.76M | 240.29M | 35.62M |
| Total Debt | 1.44M | 1.64M | 37.48M |
| Net Cash (Debt) | 170.16M | 211.55M | -2.72M |
| Net Cash Per Share | 6.21 | 17.61 | -3.54 |
| Filing Date Shares Outstanding | 42.80M | 33.21M | 7.05M |
| Total Common Shares Outstanding | 33.41M | 33.21M | 7.05M |
| Working Capital | 160.47M | 200.58M | 25.19M |
| Book Value Per Share | 4.77 | 5.99 | -2.20 |
| Tangible Book Value | 159.25M | 199.01M | -15.48M |
| Tangible Book Value Per Share | 4.77 | 5.99 | -2.20 |
Cash flow statement
Fiscal year January - December; amounts in USD.
| TTM | FY2025 | FY2024 | |
|---|---|---|---|
| Net Income | -165.12M | -153.94M | -71.47M |
| Depreciation & Amortization | 212.00K | 84.00K | |
| Asset Writedown & Restructuring Costs | 80.00M | 80.00M | 4.00M |
| Stock-Based Compensation | 14.81M | 13.30M | 4.54M |
| Other Operating Activities | 387.00K | 2.40M | 8.00K |
| Change in Accounts Receivable | -18.00M | ||
| Change in Accounts Payable | -3.49M | -5.00M | 29.31M |
| Change in Unearned Revenue | 3.12M | 4.16M | |
| Change in Other Net Operating Assets | -823.00K | 5.47M | 8.54M |
| Operating Cash Flow | -72.68M | -71.53M | -25.08M |
| Capital Expenditures | -939.00K | -919.00K | |
| Sale (Purchase) of Intangibles | -80.00M | -72.00M | |
| Investing Cash Flow | -79.17M | -72.92M | |
| Total Debt Issued | 149.92M | ||
| Net Debt Issued (Repaid) | 149.92M | ||
| Issuance of Common Stock | 177.89M | 321.89M | 1.26M |
| Repurchase of Common Stock | -177.00K | ||
| Other Financing Activities | -7.09M | 1.27M | -3.04M |
| Financing Cash Flow | 170.80M | 322.98M | 164.14M |
| Net Cash Flow | 18.95M | 178.53M | 139.06M |
| Free Cash Flow | -73.62M | -72.45M | -25.08M |
| Free Cash Flow Margin | -619.52% | -668.12% | |
| Free Cash Flow Per Share | -2.69 | -6.03 | -32.67 |
| Levered Free Cash Flow | -153.70M | ||
| Unlevered Free Cash Flow | -152.33M | ||
| Change in Working Capital | -1.19M | -13.37M | 37.85M |
Ratios
Fiscal year January - December; amounts in USD.
| TTM | FY2025 | FY2024 | |
|---|---|---|---|
| Market Capitalization | 554.27M | 231.86M | |
| Enterprise Value | 384.12M | 104.33M | |
| Last Close Price | 13.48 | 11.86 | |
| PS Ratio | 48.55 | 21.38 | |
| PB Ratio | 2.83 | 1.14 | |
| P/TBV Ratio | 3.62 | 1.17 | |
| EV/Sales Ratio | 34.23 | 9.62 | |
| Debt / Equity Ratio | 0.01 | 0.01 | -3.27 |
| Net Debt / Equity Ratio | -1.04 | -1.04 | -0.24 |
| Net Debt / EBITDA Ratio | 1.00 | 1.39 | |
| Net Debt / FCF Ratio | 2.31 | 2.92 | -0.11 |
| Asset Turnover | 0.08 | ||
| Quick Ratio | 9.26 | 6.41 | 3.62 |
| Current Ratio | 9.66 | 6.56 | 3.62 |
| Return on Equity (ROE) | -160.75% | ||
| Return on Assets (ROA) | -69.15% | ||
| Return on Capital Employed (ROCE) | -103.70% | -74.70% | -264.40% |
| Earnings Yield | -46.57% | -66.40% | |
| FCF Yield | -12.76% | -31.25% | |
| Buyback Yield / Dilution | -1,465.00% |